Staar Surgical (STAA) shares plummeted 37.39% in the pre-market session on Wednesday, following the company's disappointing fourth-quarter and full-year 2024 financial results, which were heavily impacted by weak demand and economic challenges in China, a critical market for its eye surgery products.
The company reported a net loss of $34.2 million, or $0.69 per share, for the fourth quarter, missing analyst estimates of a $0.16 loss per share. Net sales for the quarter were $48.95 million, significantly lower than the consensus estimate of $77.29 million.
The primary driver behind the weak performance was the challenges faced in China, where sales of Implantable Collamer Lenses (ICL) declined by 13% year-over-year to $161 million for fiscal 2024. Staar Surgical attributed this decline to fluctuating demand and weak consumer sentiment in China, which is expected to continue, especially in the first half of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。